U.S. Generic User Fees Might Combine Inspection Visits, Boost Foreign Cooperation
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA and the generic industry are considering ideas for combining inspections to reduce the number of visits from regulators as part of user fee discussions, while industry is concerned changes could affect cooperation with foreign entities